October 24, 2003 - Gambro has released its nine-month report for 2003.

Report highlights as reported by Gambro:

• Revenues up 8% currency adjusted
  
  
• Operating earnings, EBITDA, up 11% currency adjusted
  
  
• Earnings before tax, EBT, up 69%
  
  
• Earnings per share increased to SEK 1.58 (0.66)
  
  
• Strong operating cash flow at MSEK 1,312 (932)
  
  
• Net debt reduced by SEK 1.8 billion since January 1, 2003

Full report in pdf format.

July 28, 2003 - Gambro has released its six-month report for 2003.

Report highlights as reported by Gambro:

• Revenue growth in line with company's outlook, up 8% currency adjusted
  
  
• Operating earnings, EBITDA, up 11% currency adjusted
  
  
• Earnings before tax, EBT, up 76%
  
  
• Earnings per share increased to SEK 0.98 (0.39)
  
  
• Strong operating cash flow at MSEK 582 (480)

March 20, 2003 - Gambro has published its 2002 Annual Report on the Internet (pdf format).

February 14, 2003 - Gambro AB announced its fourth quarter and year 2002 results. Statement from Gambro (pdf format).

Full year 2002 highlights as reported by Gambro:

• Group revenues increased 9% currency adjusted, good organic growth in all business areas
  
  
• Operating earnings, EBITDA, up 11% currency adjusted
  
  
• Strong operating cash flow at MSEK 1,540 (-11)
  
  
• Earnings per share increased to SEK 1.05 (0.39); SEK 1.78 incl. reversal of tax provisions
  
  
• Dividend proposal SEK 1.10 (1.10)

Report from Reuters.

October 25, 2002 - Gambro AB announced its first nine months results for 2002.

Highlights as reported by Gambro:

• Strong revenue growth, +11% currency adjusted, with outstanding organic growth for Gambro Healthcare. U.S. revenue per treatment improved by USD 3 to USD 255.
  
  
  
• EBITDA margin for the group at 17.0%, improved from the second quarter as well as from the third quarter last year.
  - Continued margin improvement in Gambro Healthcare U.S. The combined margin for Gambro Renal Products and Gambro BCT improved from the second quarter as well as from third quarter last year.
  
  
  
• Operating cash flow improved through strong underlying performance and very well managed accounts receivable in Gambro Healthcare.
  
  
  
• Net debt reduced by MSEK 217 from second quarter.

Gambro will present the Nine Months Report 2002 at an international teleconference, which you can listen to live on Internet. The presentation will take place at 16.00 hrs CET. (10 am EDT)

September 3, 2002 - Gambro AB announced that its wholly owned subsidiary, Gambro BCT, Inc., has established a separate U.S. based company named Gambro Pathogen Reduction Technology, Inc. (PETCo). PETCo�s objective is to be the global market leader in the pathogen reduction of platelets, red blood cells and plasma. Press release from Gambro.

Here is an information page on pathogen inactivation from the Gambro web site.

July 26, 2002 - Gambro AB announced its first half results for 2002.

Highlights as reported by Gambro:

• Strong revenue growth, +10% currency adjusted, in all significant respects organic. Gambro Healthcare revenue per treatment in the US improved by USD 6 to USD 252.
  
  
• Continued strong development of operating cash flow due to strong growth within all business areas and improved performance within Gambro Healthcare.
  
  
• Cash flow, currency effects and very few acquisitions led to reduced net debt.
  
  
• EBITDA margin for the group remained stable from the first quarter this year but somewhat lower than the second quarter last year. Margin improvement in Gambro Healthcare. Gambro Renal Products� margin was somewhat reduced from last year�s high level. Gambro BCT�s margin was significantly lower in line with the strategy to widen its business scope, including expansion of PET spending.

Here is a five year chart of Gambro's stock price, earnings and dividends from Wright Research.

April 26, 2002 - Gambro AB announced its first quarter results for 2002.

Highlights as reported by Gambro:

• Group revenues increased 12 percent
  
  
• Operating earnings, EBITDA, up 6 percent with improvements in all business areas
  
  
• Strong operating cash flow

March 26, 2002 - Here is a short report on the decisions taken at the Gambro AB Annual General Meeting held March 25.

A dividend for 2001 of SEK 1.10 per share will be paid.

February 13, 2002 - Gambro annnounced its fourth quarter and year end results today.

Here is a brief summary of the results from Reuters/Yahoo.

October 25, 2001 - Gambro announced its third quarter results today and several other Gambro-related stories are in the news:

Gambro's Third Quarter Results and Nine-month Report - Today's report shows that third quarter sales rose 21 percent compared to the previous year. However, Gambro's profitability fell with the EBITDA margin at 15.9 percent in the third quarter, down from 17.6 percent a year earlier.

Gambro now reports 672 clincs and 50,300 patients worldwide. Approximately 80 percent of these are in the U.S.

New Function for Gambro Dialysis Centers - Gambro AB is teaming with Dendreon Corporation to produce cancer vaccines. Gambro Healthcare plans to use its US network of clinics as cell collection centers. Gambro BCT�s COBE Spectra� Apheresis System will be used for the cell collection procedure. The collected cells serve as a raw material component in the prodution of Dendreon�s cancer vaccines.

New Gambro Dialyzer Plant - Gambro also announced this week that it has opened a new dialyzer manufacturing plant in Germany to produce their synthetic membrane dialyzer, Polyflux.

Gambro Announces Services to Catch Fresenius - Bloomberg Financial reports that Gambro is moving to manage its clinics locally, sell new products such as a reusable synthetic dialyzers, and is introducing services such as vascular access centers.

[This message has been edited by Gary Peterson (edited 10-24-2003).]